Clinical development failure
ONP-002 is still in development, so efficacy, safety, or trial design issues could halt progress.
- Scope
- Lead program
- Materiality
- high
Oragenics Inc
Oragenics Inc. is a U.S.-based biopharmaceutical development company focused on neurology assets, with its lead program ONP-002 being developed for the treatment of mild traumatic brain injury (concussion). The company operates as a single reportable segment centered on research, nonclinical work, clinical development, and regulatory advancement of its product candidate pipeline.
| % | |
|---|---|
| Lead product candidate development | 100% Development activities for ONP-002, the company's lead neurology candidate for concussion. |
| Clinical research services | 0% Third-party clinical trial, manufacturing, and regulatory services used to advance the program. |
| Nonclinical research and development | 0% Internal and outsourced preclinical studies and discovery work supporting the pipeline. |
Oragenics does not currently sell commercial products, so its direct counterparties are primarily clinical research...
- Clinical research and development vendorsprimary
They provide trial execution, manufacturing, and regulatory support for ONP-002 development.
- Strategic licensing and partnership counterpartiesprimary
Potential partners that could fund, co-develop, or commercialize neurology assets.
- Future neurology patients and healthcare providersemerging
The eventual end users of a concussion treatment if the candidate reaches market.
Oragenics is headquartered in the United States and its development activities are managed as a single operating...
- •Headquartered in the United States
- •Clinical and regulatory work is organized as one operating segment
- •No separate geographic revenue disclosure because there is no revenue
- •U.S. capital markets are important for funding development
- •Future commercialization could be licensed into other regions
The company’s strategy is to advance ONP-002 through clinical development and IND-enabling work while seeking external...
01
Advance ONP-002 clinical developmentshort-term
The lead asset is the core value driver and the basis for future partnering or commercialization.
02
Secure external funding and partnershipsshort-term
Development requires capital and the company relies on financing or collaborations to continue operations.
03
Build a broader neurology pipelinemedium-term
Additional assets can diversify scientific risk and create more partnering opportunities.
Oragenics faces the typical risks of a clinical-stage biotechnology company: uncertain trial outcomes, regulatory...
Regulatory approval delay or denial
The business depends on IND-enabling work and future clinical/regulatory milestones.
- Scope
- FDA pathway
- Materiality
- high
Financing dilution
The company expects to raise capital through equity and debt, which can dilute existing holders.
- Scope
- Common stock, warrants, preferred shares
- Materiality
- high
Anti-dilution and conversion overhang
Series H Preferred Stock terms may increase the number of shares issued on conversion.
- Scope
- Series H Convertible Preferred Stock
- Materiality
- high
Partnering and licensing execution risk
Future funding and development plans depend partly on external alliances and agreements.
- Scope
- Strategic partnerships
- Materiality
- medium
Going concern assessment
Can affect disclosure, investor perception, and liquidity analysis
Research and development expense timing
Drives quarter-to-quarter volatility in operating loss
Legal and professional fee accruals
Can materially affect G&A expense and liabilities
Debt discount and interest expense
Affects interest expense and net loss
Convertible preferred stock and warrants
Can affect equity classification, share count, and dilution
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.\new
PTIX · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Neurogene Inc.
NGNE · Pharmaceutical Preparations
: 29/04/2026